Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease

Simple item page
dc.contributor.authorPetersons, C.
dc.contributor.authorMangesldorf, B.
dc.contributor.authorJenkins, A.
dc.contributor.authorPoljak, A.
dc.contributor.authorSmith, M.
dc.contributor.authorGreenfield, J.
dc.contributor.authorThompson, C.
dc.contributor.authorBurt, M.
dc.date.issued2013
dc.description.abstract<h4>Objective</h4>The metabolic effects of low-dose prednisolone and optimal management of glucocorticoid-induced diabetes are poorly characterized. The aims were to investigate the acute effects of low-dose prednisolone on carbohydrate metabolism and whether long-term low-dose prednisolone administration increases visceral adiposity, amplifying metabolic perturbations.<h4>Research design and methods</h4>Subjects with inflammatory rheumatologic disease without diabetes mellitus were recruited. Nine subjects (age, 59 ± 11 years) not using oral glucocorticoids were studied before and after a 7- to 10-day course of oral prednisolone 6 mg daily. Baseline data were compared with 12 subjects (age, 61 ± 8 years) using continuous long-term prednisolone (6.3 ± 2.2 mg/day). Basal endogenous glucose production (EGP) was estimated by 6,6-(2)H2 glucose infusion, insulin sensitivity was estimated by two-step hyperinsulinemic-euglycemic clamp, insulin secretion was estimated by intravenous glucose tolerance test, and adipose tissue areas were estimated by computed tomography.<h4>Results</h4>Prednisolone acutely increased basal EGP (2.44 ± 0.46 to 2.65 ± 0.35 mg/min/kg; P = 0.05) and reduced insulin suppression of EGP (79 ± 7 to 67 ± 14%; P = 0.03), peripheral glucose disposal (8.2 ± 2.4 to 7.0 ± 1.6 mg/kg/min; P = 0.01), and first-phase (5.9 ± 2.0 to 3.9 ± 1.6 mU/mmol; P = 0.01) and second-phase (4.6 ± 1.7 to 3.6 ± 1.4 mU/mmol; P = 0.02) insulin secretion. Long-term prednisolone users had attenuated insulin suppression of EGP (66 ± 14 vs. 79 ± 7%; P = 0.03) and nonoxidative glucose disposal (44 ± 24 vs. 62 ± 8%; P = 0.02) compared with nonglucocorticoid users, whereas basal EGP, insulin secretion, and adipose tissue areas were not significantly different.<h4>Conclusions</h4>Low-dose prednisolone acutely perturbs all aspects of carbohydrate metabolism. Long-term low-dose prednisolone induces hepatic insulin resistance and reduces peripheral nonoxidative glucose disposal. We conclude that hepatic and peripheral insulin sensitivity should be targeted by glucose-lowering therapy for glucocorticoid-induced diabetes.
dc.description.statementofresponsibilityCarolyn J. Petersons, Brenda L. Mangelsdorf, Arthur B. Jenkins, Anne Poljak, Malcolm D. Smith, Jerry R. Greenfield, Campbell H. Thompson and Morton G. Burt
dc.identifier.citationDiabetes Care, 2013; 36(9):2822-2829
dc.identifier.doi10.2337/dc12-2617
dc.identifier.issn0149-5992
dc.identifier.issn1935-5548
dc.identifier.orcidThompson, C. [0000-0002-5164-3327]
dc.identifier.urihttp://hdl.handle.net/2440/80685
dc.language.isoen
dc.publisherAmer Diabetes Assoc
dc.rights© 2013 American Diabetes Association
dc.source.urihttps://doi.org/10.2337/dc12-2617
dc.subjectLiver
dc.subjectHumans
dc.subjectRheumatic Fever
dc.subjectInsulin Resistance
dc.subjectPrednisolone
dc.subjectGlucose
dc.subjectAnti-Inflammatory Agents
dc.subjectGlucose Clamp Technique
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectAdiposity
dc.subjectCarbohydrate Metabolism
dc.titleEffects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications